"Vigabatrin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID. (From Martindale The Extra Pharmacopoeia, 31st ed)
| Descriptor ID |
D020888
|
| MeSH Number(s) |
D02.241.081.114.500.350.900 D12.125.190.350.900
|
| Concept/Terms |
Vigabatrin- Vigabatrin
- gamma-Vinyl-GABA
- gamma Vinyl GABA
- gamma-Vinyl-gamma-Aminobutyric Acid
- Acid, gamma-Vinyl-gamma-Aminobutyric
- gamma Vinyl gamma Aminobutyric Acid
|
Below are MeSH descriptors whose meaning is more general than "Vigabatrin".
Below are MeSH descriptors whose meaning is more specific than "Vigabatrin".
This graph shows the total number of publications written about "Vigabatrin" by people in this website by year, and whether "Vigabatrin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vigabatrin" by people in Profiles.
-
Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) Trial. Pediatr Neurol. 2024 Oct; 159:62-71.
-
Early Subclinical Status Epilepticus May Contribute to Developmental Delays in Infants With Tuberous Sclerosis Complex. Pediatr Neurol. 2024 Aug; 157:39-41.
-
Inaccuracies in Parental Reporting of Treated Epileptic Spasms: Both Under- and Over-Reporting. Pediatr Neurol. 2023 Aug; 145:119-123.
-
Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies. Epilepsia. 2023 07; 64(7):1821-1832.
-
Vigabatrin: Lessons Learned From the United States Experience. J Neuroophthalmol. 2018 12; 38(4):442-450.
-
Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. Epilepsy Behav. 2016 07; 60:174-180.
-
Sabril? registry 5-year results: Characteristics of adult patients treated with vigabatrin. Epilepsy Behav. 2016 Mar; 56:15-9.
-
Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms. Neurobiol Dis. 2015 Oct; 82:1-11.
-
T2 hyperintense signal of the central tegmental tracts in children: disease or normal maturational process? Neuroradiology. 2012 Aug; 54(8):863-71.
-
Registry initiated to characterize vision loss associated with vigabatrin therapy. Epilepsy Behav. 2011 Dec; 22(4):710-7.